Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine

Clouser, Christine L.; Chauhan, Jay; Bess, Matthew A.; Oploo, Jessica L. van; Zhou, Ding; Dimick-Gray, Sarah; Mansky, Louis M.; Patterson, Steven

doi:10.1016/j.bmcl.2012.08.108

Cited by 82 publications

(68 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously demonstrated that RV, which had no direct antiviral effects against wild-type HIV-1 or against thymidine or adenosine analog-resistant mutants, enhances the antiviral activity of NRTIs [3, 4]. Clouser et al have shown that RV and nucleoside analog decitabine are synergistic against HIV-1 [13]. …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1

Heredia

Davis

Amin

et al. 2014

Aids

View full text Add to dashboard Cite

Objective The M184V mutation in the HIV-1 reverse transcriptase (RT) gene is frequent (> 50 %) in patients, both in resource-rich and resource-limited countries, conferring high-level resistance (> 100-fold) to the cytosine analog RT inhibitors 3TC and FTC. The RT enzyme of M184V HIV-1 mutants has reduced processivity, resulting in reduced viral replication, particularly at low nucleotide (dNTP) levels. We hypothesized that lowering intracellular dNTPs with Resveratrol (RV), a dietary supplement, could interfere with replication of M184V HIV-1 mutants. Design and Methods Evaluation of the activity of RV on infection of primary peripheral blood lymphocytes (PBLs) by wild type and M184V mutant HIV-1. We assayed both molecular clones and primary isolates of HIV-1, containing M184V alone and in combination with other RT mutations. Viral infection was quantified by p24 ELISA and by quantitative real-time PCR analysis. Cell viability was measured by MTT assays. Results In virus infectivity assays, RV did not inhibit replication of wild-type NL43 (RV EC50 > 10 µM), but it inhibited NL43 184V mutant (RV EC50 = 5.8 µM). These results were confirmed by real-time PCR analysis of early and late products of reverse transcription. RV inhibited molecular clones and primary isolates carrying M184V, alone or in combination with other RT mutations (RV EC50 values ranging 2.5–7.7 µM). Conclusions RV inhibits HIV-1 strains carrying the M184V mutation in RT. We propose RV as a potential adjuvant in HIV-1 therapy, particularly in resource limited settings, to help control FTC-resistant M184V HIV-1 mutants.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It is also possible that enterohepatic recirculation through biliary secretion of metabolites and subsequent deconjugation by gut microflora could explain the in vivo activity of RV [22]. In an effort to boost RV bioavailability, several derivatives and delivery approaches are being pursued [13, 23, 24]. …”

Section: Discussionmentioning

confidence: 99%

Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1

Heredia

Davis

Amin

et al. 2014

Aids

View full text Add to dashboard Cite

show abstract

“…It is a significant component of red wine and has been suggested to explain the “French paradox” in which the southwestern population of France has a low occurrence of coronary heart diseases and cardiovascular diseases despite a high saturated fat diet (Renaud and de Lorgeril, 1992). It has anti-cancer (Udenigwe et al , 2008), anti-inflammatory (Chen et al , 2005a; Udenigwe et al , 2008), antiapoptotic (Baarine et al , 2011; Nicolini et al , 2001), antioxidant (Chang et al , 2012; Spanier et al , 2009), antidiabetic (Chang et al , 2012), and antiviral (Clouser et al , 2012) properties. It is a potent activator of SIRT1 by lowering SIRT1’s Michaelis constant for its acetylated substrate and NAD + (Howitz et al , 2003).…”

Section: Pharmacologic Therapiesmentioning

confidence: 99%

Mitochondrial function in hypoxic ischemic injury and influence of aging

Ham

Raju

2017

Progress in Neurobiology

260

205

View full text Add to dashboard Cite

Mitochondria are a major target in hypoxic/ischemic injury. Mitochondrial impairment increases with age leading to dysregulation of molecular pathways linked to mitochondria. The perturbation of mitochondrial homeostasis and cellular energetics worsens outcome following hypoxic-ischemic insults in elderly individuals. In response to acute injury conditions, cellular machinery relies on rapid adaptations by modulating posttranslational modifications. Therefore, post-translational regulation of molecular mediators such as hypoxia-inducible factor 1α (HIF-1α), peroxisome proliferator-activated receptor γ coactivator α (PGC-1α), c-MYC, SIRT1 and AMPK play a critical role in the control of the glycolytic-mitochondrial energy axis in response to hypoxic-ischemic conditions. The deficiency of oxygen and nutrients leads to decreased energetic reliance on mitochondria, promoting glycolysis. The combination of pseudohypoxia, declining autophagy, and dysregulation of stress responses with aging adds to impaired host response to hypoxic-ischemic injury. Furthermore, intermitochondrial signal propagation and tissue wide oscillations in mitochondrial metabolism in response to oxidative stress are emerging as vital to cellular energetics. Recently reported intercellular transport of mitochondria through tunneling nanotubes also play a role in the response to and treatments for ischemic injury. In this review we attempt to provide an overview of some of the molecular mechanisms and potential therapies involved in the alteration of cellular energetics with aging and injury with a neurobiological perspective.

show abstract

“…Antiviral effects of RSV have been investigated in several human and animal viruses including influenza A virus (Palamara et al., 2005), Epstein‐Bar virus (Chen, Qiao et al., 2012), herpes simplex virus (Chen, Qiao et al., 2012), HIV (Clouser et al., 2012), and hepatitis C virus (Nakamura et al., 2010). Results from most of these studies indicate that RSV can prevent inhibiting protein synthesis and thus inhibit virus proliferation (Yang et al., 2015).…”

Section: Resveratrol and Diseasesmentioning

confidence: 99%

Resveratrol: A miraculous natural compound for diseases treatment

Koushki

Amiri-Dashatan

Ahmadi

et al. 2018

Food Science & Nutrition

169

109

View full text Add to dashboard Cite

Resveratrol (3, 5, 4′‐trihydroxystilbene) is a nonflavonoid polyphenol that naturally occurs as phytoalexin. It is produced by plant sources such as grapes, apples, blueberries, plums, and peanut. This compound has critical roles in human health and is well known for its diverse biological activities such as antioxidant and anti‐inflammatory properties. Nowadays, due to rising incidence of different diseases such as cancer and diabetes, efforts to find novel and effective disease‐protective agents have led to the identification of plant‐derived compounds such as resveratrol. Furthermore, several in vitro and in vivo studies have revealed the effectiveness of resveratrol in various diseases such as diabetes mellitus, cardiovascular disease, metabolic syndrome, obesity, inflammatory, neurodegenerative, and age‐related diseases. This review presents an overview of currently available studies on preventive properties and essential molecular mechanisms involved in various diseases.

show abstract

Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine

Cited by 82 publications

References 25 publications

Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1

Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1

Mitochondrial function in hypoxic ischemic injury and influence of aging

Resveratrol: A miraculous natural compound for diseases treatment

Contact Info

Product

Resources

About